This inventor holds 1 USPTO granted patent and 2 published patent applications and 2 EPO patents. Top assignee: The University of Birmingham. Active years: 2014.
Company Filing History:
Years Active: 2014
Title: Simon Ball - Innovator in HLA Peptide Therapy
Introduction
Simon Ball is a notable inventor based in Birmingham, GB. He has made significant contributions to the field of medical science, particularly in the area of HLA peptide therapy. His innovative work focuses on developing treatments that can prevent allograft rejection, which is crucial for transplant patients.
Latest Patents
Simon Ball holds 1 patent for his invention related to HLA peptide therapy. This invention provides polypeptides derived from a major histocompatibility complex (MHC) class I human leukocyte antigen (HLA), such as HLA-A2, along with derivatives or analogues thereof. The polypeptides, derivatives, and analogues can be utilized to treat or prevent allosensitisation, which is essential for improving transplant outcomes.
Career Highlights
Throughout his career, Simon has worked with esteemed institutions, including the University of Birmingham and Circassia Limited. His experience in these organizations has allowed him to advance his research and contribute to the development of innovative therapies.
Collaborations
Simon Ball has collaborated with various professionals in his field, including Bernard Maillere. These partnerships have played a vital role in enhancing the impact of his research and inventions.
Conclusion
In summary, Simon Ball is a distinguished inventor whose work in HLA peptide therapy has the potential to transform the treatment of allograft rejection. His contributions to medical science are invaluable and highlight the importance of innovation in healthcare.